Reproterol: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Inhalation/Respiratory
Acute bronchospasm

Adult: As metered-dose aerosol containing 500 mcg/inhalation: 1 or 2 inhalations, repeated every 3-6 hr as required.

Intravenous
Status asthmaticus

Adult: 90 mcg via slow IV inj, may repeat after 10 minutes if needed.

Oral
Acute bronchospasm

Adult: As hydrochloride: 10-20 mg tid.
Child: As hydrochloride: As metered-dose aerosol: 6-12 yr: 1 inhalation (500 mcg) every 3-6 hr.

Contraindications

Hypertrophic obstructive cardiomyopathy, tachyarrhythmia, phaechromocytoma, hypersensitivity.

Special Precautions

Hyperthyroidism, myocardial insufficiency, arrhythmias, susceptibility to QT-interval prolongation, hypertension, severe asthma and diabetes mellitus. Monitor plasma potassium concentrations. Pregnancy and lactation.

Adverse Reactions

Fine tremor of skeletal muscle, palpitations, muscle cramps, tachycardia, nervous tension, headache, peripheral vasodilatation, hypersensitivity reactions.
Potentially Fatal: Large doses may result in severe hypokalaemia.

Drug Interactions

Increased risk of hypokalaemia when used with potassium-depleting drugs eg. corticosteroids, diuretics and theophylline. May enhance neuromuscular blockade produced by pancuronium and vecuronium. Increased risk of digitalis-induced arrhythmias.

Action

Description: Reproterol is a direct-acting sympathomimetic with predominantly β-adrenergic activity and a selective action on β₂-receptors.

MIMS Class

Antiasthmatic & COPD Preparations

Disclaimer: This information is independently developed by MIMS based on Reproterol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com